公开(公告)号：US20190085035A1

公开(公告)日：2019-03-21

申请号：US16145063

申请日：2018-09-27

Applicant: OXTHERA INTELLECTUAL PROPERTY AB

Inventor： Elisabeth Lindner ,  Helena Cowley ,  Aaron Cowley ,  Maria Åkerman

IPC: C07K14/195 ,  C12N9/88 ,  A61K38/16 ,  C12N9/04 ,  C12N9/06 ,  C12N9/02 ,  C12N9/10 ,  C12N9/14 ,  A61K35/74 ,  A61K38/00

Abstract: The present invention relates to a secretagogue compound derived from oxalate degrading bacteria, for use in the treatment of an oxalate related disease and/or oxalate related imbalance in a subject, wherein the administration of the secretagogue results in a reduction of urinary oxalate and/or plasma oxalate in the subject. The invention further relates to a pharmaceutical composition comprising such a secretagogue compound, a method for treating a subject suffering from an oxalate related disease, and to a method for preparing a secretagogue.

公开(公告)号：US10988510B2

公开(公告)日：2021-04-27

申请号：US16145063

申请日：2018-09-27

Applicant: OXTHERA INTELLECTUAL PROPERTY AB

Inventor： Elisabeth Lindner ,  Helena Cowley ,  Aaron Cowley ,  Maria Åkerman

IPC: C07K14/195 ,  A61K38/16 ,  C12N9/04 ,  C12N9/06 ,  C12N9/02 ,  C12N9/10 ,  C12N9/14 ,  C12N9/88 ,  A61K35/74 ,  A61K38/00

Abstract: The present invention relates to a secretagogue compound derived from oxalate degrading bacteria, for use in the treatment of an oxalate related disease and/or oxalate related imbalance in a subject, wherein the administration of the secretagogue results in a reduction of urinary oxalate and/or plasma oxalate in the subject. The invention further relates to a pharmaceutical composition comprising such a secretagogue compound, a method for treating a subject suffering from an oxalate related disease, and to a method for preparing a secretagogue.

公开(公告)号：US10125176B2

公开(公告)日：2018-11-13

申请号：US14902484

申请日：2014-07-03

Applicant: OXTHERA INTELLECTUAL PROPERTY AB

Inventor： Elisabeth Lindner ,  Helena Cowley ,  Aaron Cowley ,  Maria Akerman

IPC: C12N9/00 ,  C07K14/195 ,  A61K38/16 ,  C12N9/04 ,  C12N9/06 ,  C12N9/02 ,  C12N9/10 ,  C12N9/14 ,  C12N9/88 ,  A61K35/74 ,  A61K38/00

Abstract: The present invention relates to a secretagogue compound derived from oxalate degrading bacteria, for use in the treatment of an oxalate related disease and/or oxalate related imbalance in a subject, wherein the administration of the secretagogue results in a reduction of urinary oxalate and/or plasma oxalate in the subject. The invention further relates to a pharmaceutical composition comprising such a secretagogue compound, a method for treating a subject suffering from an oxalate related disease, and to a method for preparing a secretagogue.